Javascript must be enabled to continue!
Accelerating AutoDock VINA with GPUs
View through CrossRef
AutoDock Vina is one of the most popular molecular docking tools. In the latest benchmark CASF-2016 for comparative assessment of scoring functions, AutoDock Vina won the best docking power among all the docking tools. Modern drug discovery is facing the most common scenario on large virtual screening of drug hits from huge compound databases. Due to the seriality characteristic of the AutoDock Vina algorithm, there is no successful report on its parallel acceleration with GPUs. Current acceleration of AutoDock Vina typically relies on the stack of computing power as well as the allocation of resource and tasks, such as the VirtualFlow platform. The vast resource expenditure and the high access threshold of users will seriously limit the popularity of AutoDock Vina and the flexibility of usage in modern drug discovery. Thus, the design of a new method for accelerating AutoDock Vina with GPUs is greatly needed for reducing the investment for large virtual screens, and also for a wide application in large-scale virtual screening on personal computers, station servers orcloud computing etc. Our proposed method Vina-GPU greatly raises the number of initial random conformations and reduces the search depth of each lane, and then a heterogeneous OpenCL implementation was developed to realize its parallel acceleration leveraging thousands of GPU cores. Large benchmarks show that Vina-GPU reaches a maximum of 403- fold docking acceleration against the original AutoDock Vina while ensuring their comparable docking accuracy, indicating its potential of pushing the popularization of AutoDock Vina in large virtual screens. The Vina-GPU code and tool can be freely available at http:// www.noveldelta.com/Vina_GPU for academic usage.
American Chemical Society (ACS)
Title: Accelerating AutoDock VINA with GPUs
Description:
AutoDock Vina is one of the most popular molecular docking tools.
In the latest benchmark CASF-2016 for comparative assessment of scoring functions, AutoDock Vina won the best docking power among all the docking tools.
Modern drug discovery is facing the most common scenario on large virtual screening of drug hits from huge compound databases.
Due to the seriality characteristic of the AutoDock Vina algorithm, there is no successful report on its parallel acceleration with GPUs.
Current acceleration of AutoDock Vina typically relies on the stack of computing power as well as the allocation of resource and tasks, such as the VirtualFlow platform.
The vast resource expenditure and the high access threshold of users will seriously limit the popularity of AutoDock Vina and the flexibility of usage in modern drug discovery.
Thus, the design of a new method for accelerating AutoDock Vina with GPUs is greatly needed for reducing the investment for large virtual screens, and also for a wide application in large-scale virtual screening on personal computers, station servers orcloud computing etc.
Our proposed method Vina-GPU greatly raises the number of initial random conformations and reduces the search depth of each lane, and then a heterogeneous OpenCL implementation was developed to realize its parallel acceleration leveraging thousands of GPU cores.
Large benchmarks show that Vina-GPU reaches a maximum of 403- fold docking acceleration against the original AutoDock Vina while ensuring their comparable docking accuracy, indicating its potential of pushing the popularization of AutoDock Vina in large virtual screens.
The Vina-GPU code and tool can be freely available at http:// www.
noveldelta.
com/Vina_GPU for academic usage.
Related Results
Accelerating AutoDock VINA with GPUs
Accelerating AutoDock VINA with GPUs
AutoDock Vina is one of the most popular molecular docking tools. In the latest benchmark CASF-2016 for comparative assessment of scoring functions, AutoDock Vina won the best dock...
Vina-GPU 2.0:further accelerating AutoDock Vina and its derivatives with GPUs
Vina-GPU 2.0:further accelerating AutoDock Vina and its derivatives with GPUs
Modern drug discovery typically faces large virtual screens from huge compound databases where multiple docking tools are involved for meeting various real scenes or improving the ...
Vina-GPU 2.1: towards further optimizing docking speed and precision of AutoDock Vina and its derivatives
Vina-GPU 2.1: towards further optimizing docking speed and precision of AutoDock Vina and its derivatives
AbstractAutoDock Vina and its derivatives have established themselves as a prevailing pipeline for virtual screening in contemporary drug discovery. Our Vina-GPU method leverages t...
Improving the Accuracy of AutoDock Vina by Changing the Empirical Parameters
Improving the Accuracy of AutoDock Vina by Changing the Empirical Parameters
According to the previous benchmark, Autodock Vina (Vina) achieved a very high successful-docking rate, p ̂, but give a rather a low correlation coefficient, R, for binding affinit...
Improving Ligand-Ranking of AutoDock Vina by Changing the Empirical Parameters
Improving Ligand-Ranking of AutoDock Vina by Changing the Empirical Parameters
AutoDock Vina (Vina) achieved a very high docking-success rate, p ̂, but give a rather low correlation coefficient, R, for binding affinity with respect to experiments. This low co...
Accelerating AutoDock VINA with GPUs
Accelerating AutoDock VINA with GPUs
AutoDock VINA is one of the most-used docking tools in the early stage of modern drug discovery. It uses a Monte-Carlo based iterated search method and multithreading parallelism s...
Accelerating AutoDock VINA with GPUs
Accelerating AutoDock VINA with GPUs
AutoDock VINA is one of the most-used docking tools in the early stage of modern drug discovery. It uses a Monte-Carlo based iterated search method and multithreading parallelism s...
Docking Molecular analysis of potential Drug Paritaprevir against Mycobacterium tuberculosis (Mtb)
Docking Molecular analysis of potential Drug Paritaprevir against Mycobacterium tuberculosis (Mtb)
AbstractBackgroundMycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, which kills 1.8 million annually. This is an infectious disease generally affects the lun...

